Clinical Trial Protocol
Iranian Registry of Clinical Trials

16 Sep 2026

Comparative bioequivalence study of the Rosuvastatin 20-mg tablet manufactured by Daana Pharmaceutical Company versus Crestor® (AstraZeneca Company).

Protocol summary

Study aim

Demonstration of bioequivalence of Rosuvastatin 20 mg tablet of Daana Pharmaceutical Company with Crestor® tablet manufactured by AstraZeneca company after single dose administration.

Design

Single dose, randomized and crossover bioequivalence study of Rosuvastatin 20-mg tablet by Daana Co. with Crestor® (AstraZeneca Co.) in 24 healthy male volunteers in two groups under fasting condition.

Settings and conduct

Study place and the place for Blood sample analysis are the Drug Applied Research Center affiliated to Tabriz University of Medical Science, respectively. 24 healthy male volunteers will receive each of two test or reference Rosuvastatin 20 mg tablet in random sequence according to the randomization schedule. The interval between receiving the medicine (washout period) is 7 days, If the first sequence receives Iranian medicine, they will receive brand medicine. Blood samples will be taken from all participants before and after receiving the drug at predetermined time points: 0، 1، 1.5، 2، 2.5، 3، 3.5، 4، 4.5، 5، 6، 8، 10، 12، 24، 48 and 72 hours.

Participants/Inclusion and exclusion criteria

Inclusion criteria: Healthy male subjects in the age range of 18-60 years and BMI (Body Mass Index) of 18.5-30. Exclusion criteria: Subjects with BP ≤ 90/60 mm/Hg or BP ≥ 140/90 mm/Hg Any evidence of impairment of renal, hepatic, cardiac, lung or gastrointestinal function or a history of TB, epilepsy, asthma, DM, psychosis or glaucoma and regular smoker.

Intervention groups

Intervention group 1: Rosuvastatin 20-mg tablet by Daana Co. is the test product. Intervention group 2: Crestor® (AstraZeneca Co.) is the reference product. In each period, 12 of 24 subjects will be given single dose of this product.

Main outcome variables

Peak Plasma Concentration (Cmax); Area under the concentration-time curve (AUC).

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20200407046981N21**
Registration date: **2021-11-04, 1400/08/13**
Registration timing: **prospective**

Last update: **2021-11-04, 1400/08/13**
Update count: **0**

Registration date

2021-11-04, 1400/08/13

Registrant information

Name

Fatima Molavi

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 41 3336 2700

Email address

molavif@tbzmed.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2021-11-22, 1400/09/01

Expected recruitment end date

2022-01-21, 1400/11/01

Actual recruitment start date

empty

Actual recruitment end date
empty
Trial completion date
empty

Scientific title
Comparative bioequivalence study of the Rosuvastatin 20-mg tablet manufactured by Daana Pharmaceutical Company versus Crestor® (AstraZeneca Company).

Public title
Study of absorption and elimination rate of Rosuvastatin 20-mg tablet in comparison with Rosuvastatin brand tablet (Crestor®).
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
The weight limit of each volunteer should be between 60 and 100 kg. All volunteers must be non-smokers. They must be healthy in terms of liver, kidney, respiratory system, mental and other general health characteristics that will be assessed. Candidates who have consented to the consent form.
Exclusion criteria:
Known hypersensitivity or idiosyncratic reaction to Rosuvastatin or any ingredients. Subjects with BP ≤ 90/60 mm/Hg or BP ≥ 140/90 mm/Hg. Regular smoker who smokes more than ten cigarettes daily. Taking any medicine during two weeks before dosing.
Age
From **18 years** old to **60 years** old
Gender
Male

Phase
Bioequivalence
Groups that have been masked
No information
Sample size
Target sample size: **24**
Randomization (investigator's opinion)
Randomized
Randomization description
To randomly assign people in two groups, 24 cards with numbers 1 to 24 will be used in closed envelopes that are arranged irregularly. Each candidate will pick up an envelope after entering the study, and numbers 1-12 will be in group A and numbers 13-24 will be in group B. Group A will receive intervention 1 and group B will receive intervention 2, and after the first period, the interventions of the both groups will change for the second period.
Blinding (investigator's opinion)
Not blinded
Blinding description
Placebo
Not used
Assignment
Crossover
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Ethics committee of Tabriz University of Medical Science
Street address
Third floor, central building No. 2, Golgasht street, Tabriz University of Medical Science, Tabriz, Iran
City
Tabriz
Province
East Azarbaijan
Postal code
5166614766
Approval date
2021-10-25, 1400/08/03
Ethics committee reference number
IR.TBZMED.REC.1400.618

Health conditions studied

1

Description of health condition studied
Bioequivalence study
ICD-10 code
ICD-10 code description

Primary outcomes

1

Description
Peak Plasma Concentration (Cmax)
Timepoint
At 0 (before dosing), 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 24, 48 and 72 hours after dosing
Method of measurement
High-performance liquid chromatography—mass spectrometry (HPLC-MS)

Secondary outcomes

1

Description
AUC (Area Under the Concentration-Time Curve)
Timepoint
At 0 (before dosing), 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 24, 48 and 72 hours after dosing
Method of measurement
Using non-compartmental model of Win-Nonlin Professional software version 3.2.A (Pharsight Corporation, USA) or SPSS

Intervention groups

1

Description
Intervention group 1: In this group, volunteers are given a single oral dose of Rosuvastatin 20-mg tablet produced by Daana Co. (Domestic). In each period, 12 of 24 subjects will be given single oral dose of this product.
Category
Treatment - Drugs

2

Description
Intervention group 2: In this group, volunteers are given a single oral dose of Rosuvastatin 20-mg tablet (Crestor), produced by AstraZeneca Company (Brand). In each period, 12 of 24 subjects will be given single oral dose of this product.
Category
Treatment - Drugs

Recruitment centers

1

Recruitment center
Name of recruitment center
Drug Applied Research Center
Full name of responsible person
Dr Hamed Hamishehkar
Street address
Drug Applied Research Center, In front of Shahid Madani Hospital, Daneshghah Blvd, Tabriz, Iran
City
Tabriz
Province
East Azarbaijan
Postal code
5165665811
Phone
+98 41 3336 7914
Fax
+98 41 3336 7914
Email
hamishehkar.hamed@gmail.com
Web page address
https://darc.tbzmed.ac.ir/

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Daana pharmaceutical company
Full name of responsible person
Ahmad Kharazi
Street address
East Azerbaijan Province, Basmenj, Tehran - Tabriz Fwy
City
Tabriz
Province
East Azarbaijan
Postal code
5495151673
Phone
+98 41 3630 0586
Fax
+98 41 3630 0591
Email
name@domain.ac.ir
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Daana pharmaceutical company
Proportion provided by this source
100
Public or private sector
Private
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Industry

Person responsible for general inquiries

Contact
Name of organization / entity
Tabriz University of Medical Sciences
Full name of responsible person
Dr Hamed Hamishehkar
Position
Professor
Latest degree
Ph.D.
Other areas of specialty/work
Pharmaceutics
Street address
Drug Applied Research Center, In front of Shahid Madani Hospital, Daneshghah Blvd, Tabriz, Iran
City
Tabriz
Province
East Azarbaijan
Postal code
5165665811
Phone
+98 41 3336 7914
Email
Hamishehkar.hamed@gmail.com

Person responsible for scientific inquiries

Contact

Name of organization / entity
Esfahan University of Medical Sciences
Full name of responsible person
Dr Jaber Emami
Position
Professor
Latest degree
Ph.D.
Other areas of specialty/work
Pharmaceutics
Street address
Hezarjarib St., School of Pharmacy and Pharmaceutical Sciences , Isfahan, Iran
City
Isfahan
Province
Isfehan
Postal code
8174673461
Phone
+98 31 3792 7111
Fax
+98 31 3668 0011
Email
Emami@pharm.mui.ac.ir

Person responsible for updating data

Contact
Name of organization / entity
Tabriz University of Medical Sciences
Full name of responsible person
Fatima Molavi
Position
PhD student of Pharmaceutics
Latest degree
Medical doctor
Other areas of specialty/work
Pharmaceutics
Street address
Drug Applied Research Center, In front of Shahid Madani Hospital, Daneshghah Blvd, Tabriz, Iran
City
Tabriz
Province
East Azarbaijan
Postal code
5165665811
Phone
+98 41 3336 2700
Fax
Email
Molavif@tbzmed.ac.ir

Sharing plan

Deidentified Individual Participant Data Set (IPD)
Undecided - It is not yet known if there will be a plan to make this available
Study Protocol
Undecided - It is not yet known if there will be a plan to make this available
Statistical Analysis Plan
No - There is not a plan to make this available
Informed Consent Form
Undecided - It is not yet known if there will be a plan to make this available
Clinical Study Report
Undecided - It is not yet known if there will be a plan to make this available
Analytic Code
Undecided - It is not yet known if there will be a plan to make this available
Data Dictionary
Undecided - It is not yet known if there will be a plan to make this available